

Association between the loudness dependence of auditory evoked potentials and age in patients with schizophrenia and depression

Journal of International Medical Research
50(7) 1–15

© The Author(s) 2022

Article reuse guidelines:

sagepub.com/journals-permissions

DOI: 10.1177/03000605221109789

journals.sagepub.com/home/imr

Kuk-In Jang¹ , Sungkean Kim², Chany Lee^{1,*}
and Jeong-Ho Chae^{3,*}

Abstract

Objective: Although serotonergic dysfunction is significantly associated with major depressive disorder (MDD) and schizophrenia (SCZ), comparison of serotonergic dysfunction in both diseases has received little attention. Serotonin hypotheses have suggested diminished and elevated serotonin activity in MDD and SCZ, respectively. However, the foundations underlying these hypotheses are unclear regarding changes in serotonin neurotransmission in the aging brain. The loudness dependence of auditory evoked potentials (LDAEP) reflects serotonin neurotransmission. The present study compared the LDAEP between patients with SCZ or MDD and healthy controls (HCs). We further examined whether age was correlated with the LDAEP and clinical symptoms.

Methods: This prospective clinical study included 105 patients with SCZ ($n = 54$) or MDD ($n = 51$). Additionally, 35 HCs were recruited for this study. The LDAEP was measured on the midline channels via 62 electroencephalography channels.

Results: Patients with SCZ or MDD showed a significantly smaller mean LDAEP than those in HCs. The LDAEP was positively correlated with age in patients with SCZ or MDD.

Conclusions: Changes in central serotonergic activity could be indicated by evaluating the LDAEP in patients with SCZ or MDD. Age-related reductions in serotonergic activity may be screened using the LDAEP in patients with SCZ or MDD.

³Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

*These authors contributed equally to this work.

Corresponding author:

Chany Lee, Department of Cognitive Science Research, Korea Brain Research Institute (KBRI), 61 Cheomdan-ro, Dong-gu, Daegu 41068, Republic of Korea.
Email: chanylee@kbri.re.kr

¹Cognitive Science Research Group, Korea Brain Research Institute (KBRI), Daegu, Republic of Korea

²Department of Human-Computer Interaction, Hanyang University, Ansan, Republic of Korea



Keywords

Schizophrenia, major depressive disorder, loudness dependence of the auditory evoked potential, age, serotonergic activity, electroencephalography

Date received: 3 December 2021; accepted: 24 May 2022

Introduction

Serotonergic dysfunction can lead to major pathological features in patients with schizophrenia (SCZ) and major depressive disorder (MDD).¹⁻³ However, comparison of serotonergic activity between the two diseases has received little attention. Some studies have hypothesized that patients with MDD⁴ have diminished serotonin neurotransmitter levels and those with SCZ exhibit elevated serotonergic neurotransmission.⁵ However, the pathological complexity underlying these changes in serotonin neurotransmission is not clearly understood.⁶⁻⁹ MDD is a heterogeneous disorder because only 30% to 40% of patients respond to antidepressants.^{10,11} SCZ also shows heterogeneity, and the understanding of the serotonergic neuropathological effects on the brain is unclear.^{12,13} Thus, a need exists to compare the changes in the central serotonergic activity in both diseases.

The loudness dependence of auditory evoked potentials (LDAEP), which is measured by electroencephalography (EEG), has been proposed as a clinical biomarker for psychiatric disorders.¹⁴⁻²¹ Serotonergic activity is negatively correlated with the LDAEP in the brain,²² which represent slope variations in the neural responses to auditory stimuli.²³⁻²⁵ A previous study found that shallower LDAEP slopes reflect elevated serotonin transmission in the dorsal raphe nucleus.²⁶ Patients with SCZ showed increased serotonergic activity compared with those with other psychiatric disorders and healthy controls (HCs).^{18,27,28}

However, the significance of the LDAEP in SCZ and MDD has been focused on symptomatic and subclinical changes and treatment responses.^{14,19,29-31} In patients with SCZ, the LDAEP predicts the risk of disease progression.³² The LDAEP also predicts treatment responses to antidepressants and brain stimulation in patients with MDD.^{14,33,34}

Serotonin receptor stimulation results in perceptual disturbances such as hallucinations in patients with SCZ,⁵ and serotonergic activity has been shown to play important roles in both SCZ and MDD.^{35,36} Moreover, antidepressants can increase the number of presynaptic serotonergic neurons in patients with MDD.³⁷ In addition, serotonin activity may modulate symptom severity and treatment responses in patients with SCZ and MDD.³⁸⁻⁴⁰ Although previous studies have reported that the LDAEP did not differ between patients with MDD and HCs,^{18,41} these potentials could predict treatment responses to antidepressants such as selective serotonin reuptake inhibitors (SSRIs) in MDD.^{42,43} Furthermore, the effect of age on the LDAEP has been reported through a pathway model in which, according to sex, age predicted the LDAEP in patients with MDD.⁴⁴ Patients with SCZ showed a negative correlation between the LDAEP and chronicity of illness, but these findings had a low statistical power.¹⁹

Serotonergic neurons are altered during aging. For example, elderly people with depression show decreased serotonergic activity,^{4,45} and age-related changes in

serotonin neurotransmission modulate sensory perceptions.^{46–48} One study found that 5-hydroxytryptamine 2 (5-HT₂) receptor binding was significantly attenuated with age in patients with SCZ and HCs.⁴⁹

The current study was performed to examine the changes in serotonin transmission in patients with SCZ and MDD and the age-related alterations in serotonergic activity. Therefore, we compared the LDAEP between patients with SCZ or MDD and HCs. Additionally, we explored the association between age and LDAEP in patients with SCZ or MDD. We hypothesized that patients with SCZ would have a smaller LDAEP than patients with MDD and HCs, indicating increased serotonin neurotransmission in patients with SCZ. We further hypothesized that the LDAEP would correlate with age in patients with SCZ or MDD.

Methods

Participants

All participants were native Koreans and were diagnosed and screened using the Mini International Neuropsychiatric Interview of the *Diagnostic and Statistical Manual of Mental Disorders, 5th Edition*. Assessments using the Positive and Negative Syndrome Scale (PANSS)⁵⁰ were performed in patients with SCZ by a trained psychiatrist who was not involved in the present study. Patients with MDD were evaluated using the Hamilton Depression Rating Scale and Hamilton Anxiety Rating Scale^{51,52} by a trained psychiatrist. In addition, measurements with the Beck Depression Inventory (BDI), which is a self-rating scale, were conducted in patients with MDD and HCs.⁵³ This prospective clinical research report was approved by the Institutional Review Board of Seoul St. Mary's Hospital College of Medicine, The Catholic University of

Korea (approval number: KC09FZZZ0211). Written informed consent was obtained from all participants. All experimental procedures followed the relevant Equator guidelines, and the reporting of this study conforms to STROBE guidelines.⁵⁴ All patient details were de-identified.

EEG recordings

The participants were seated in a comfortable chair in a sound-attenuated room. The EEG data were recorded using a NeuroScan SynAmps amplifier (Compumedics USA, El Paso, TX, USA) with a head cap mounted with AgCl electrodes according to the international extended 10–20 system. The following 62 scalp electrodes were employed: FP1, FPz, FP2, AF3, AF4, F7, F5, F3, F1, Fz, F2, F4, F6, F8, FT7, FC5, FC3, FC1, FCz, FC2, FC4, FC6, FT8, T7, C5, C3, C1, Cz, C2, C4, C6, T8, TP7, CP5, CP3, CP1, CPz, CP2, CP4, CP6, TP8, P7, P5, P3, P1, Pz, P2, P4, P6, P8, PO7, PO5, PO3, POz, PO4, PO6, PO8, CB1, O1, Oz, O2, and CB2. Electrooculography electrodes were placed above and below the left eye to detect vertical movement and at the outer canthus of each eye to measure horizontal movement. Bandpass filtering was applied at 1 to 100 Hz, with a sampling rate of 1000 Hz. Reference electrodes were placed on both mastoids, and the ground electrode was placed on the forehead. The impedance was maintained below 5 k Ω .

LDAEP paradigm and analysis

The auditory stimulation protocol consisted of 500 stimuli with a fixed interstimulus interval of 2000 ms. Tones of 1000 Hz with a duration of 100 ms (rise and fall time: 10 ms) were delivered at five intensities (60, 70, 80, 90, and 100 dB sound pressure level) through MDR-D777 headphones (Sony, Tokyo, Japan). A total of 500 stimuli, including 100 stimuli of each intensity,

were triggered via the STIM2 system (Compumedics USA) to ensure accurate synchronization between the stimuli and EEG recordings. Participants were instructed to listen to sounds and look at a fixation cross displayed on the middle of the monitor screen. To improve compliance with the experiment, the duration of a single EEG session was limited to 15 minutes. A trained evaluator with no information about the origin of the data removed gross artifacts through visual inspection. Artifacts related to eye blinks were removed using an established mathematical procedure.⁵⁵ On the basis of the vertical electrooculography results, positive and negative components exceeding $300\ \mu\text{V}$ from before and after the onset stimulus ($-100\ \text{ms}$ to $300\ \text{ms}$) were removed. Data were epoched in the range of $-100\ \text{ms}$ to $700\ \text{ms}$. Pre-stimulus baseline correction and linear detrending were applied to all electrodes. Artifacts exceeding $\pm 100\ \mu\text{V}$ were rejected at all electrode sites. Off-line bandpass filtering was applied at 1 to 30 Hz. After preprocessing the data for each sound intensity, the trials were averaged at five electrodes (Fz, Cz, C3, C4, and Oz). N100-P200 peak detection was performed using MATLAB 2019 software (Mathworks Inc., Natick, MA, USA) and Scan 4.5 software (Compumedics USA). For each intensity, the most negative peak amplitude of the N100 component was defined between 80 ms and 160 ms after the stimulus onset, while the most positive peak amplitude of the P200 component was defined between 130 ms and 280 ms. After completion of signal processing, the LDAEP was calculated as the slope variation for five stimulus intensities using the linear regression slope.⁴⁴

Statistical analyses

Demographic data, including age, sex, and symptom scores, were analyzed using the

chi-squared test, one-way analysis of variance with a post-hoc test, or a t-test as appropriate. To determine the interaction effect between the LDAEP and group, we analyzed the group differences in the LDAEP using repeated-measures analysis of covariance. The between-subject factor was group, and the within-subject factors were the LDAEP at the five electrode sites. Age and sex were controlled as covariates. In addition, for each single electrode, the LDAEP was compared among the groups based on multivariate analysis of covariance (MANCOVA), controlling for age and sex as covariates. The LDAEP was also compared between patients with SCZ and those with MDD with age, sex, and drug usage serving as covariates. In the MANCOVA analyses, the significance level was set at $p < 0.008$ (two-tailed), considering multiple comparisons based on the Bonferroni correction.⁵⁶ Furthermore, partial correlation analysis was performed among age, LDAEP, and symptom severity in each group after controlling for drug usage and sex. Binary classification of medication was performed based on the presence or absence of the use of drugs that could modulate the LDAEP (Table 1). Forty-seven patients with SCZ and 12 patients with MDD were administered serotonin-related drugs in the current study. In the correlation analyses, p-values were adjusted using Bonferroni correction with a significance level of $p < 0.003$. All statistical procedures were performed using IBM SPSS for Windows, version 21.0 (IBM Corp., Armonk, NY, USA). Additionally, we calculated the required sample size using G*Power software (Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Nordrhein-Westfalen, Germany).⁵⁷ This study used F-tests with MANCOVA with repeated measures and within-between interactions. The effect size of this study was set at 0.25, the alpha value was set at 0.05, and

Table 1. Drug information in patients with SCZ and MDD.

DRUG	SCZ	N	MDD
Amisulpride	7		–
Aripiprazole	9		–
Blonanserin	3		–
Clozapine	1		–
Olanzapine	16		–
Paliperidone	11		–
Quetiapine	11		–
Risperidone	1		–
Alprazolam	–		5
Escitalopram	–		1
Etizolam	–		1
Lorazepam	–		2
Mirtazapine	–		1
Paroxetine	–		2
Sertraline	–		1
Venlafaxine	–		5
5-HT-related drug	47		12

Drugs shown in bold are serotonin receptor antagonists used to treat patients with SCZ.

Abbreviations: MDD, major depressive disorder; SCZ, schizophrenia; 5-HT, 5-hydroxytryptamine.

the power was set at 0.80. The minimum sample size required was 125.

Results

Fifty-four outpatients with SCZ (18 men and 36 women) and 51 outpatients with MDD (13 men and 38 women) were selectively enrolled according to the research participation criteria. The mean ages of patients with SCZ and MDD were 38.98 ± 16.32 years and 34.72 ± 10.98 years, respectively. Thirty-five HCs (17 men and 18 women) were recruited through community newspapers. Their mean age was 41.40 ± 11.38 years. The age of all participants ranged from 16 to 82 years (mean age: 38.03 ± 13.56 years). Comparisons of demographic data and the LDAEP are shown in Table 2. We compared BDI scores between two groups, patients with MDD and HCs. Patients with MDD had higher BDI scores

than HCs ($t = 9.75$, $p < 0.001$). For the comparison of the LDAEP, the interaction effect between the LDAEP and group was significant ($f = 11.39$, $p < 0.001$, $\eta_p^2 = 0.14$); patients with SCZ or MDD exhibited a smaller LDAEP than those in HCs ($f_{(2, 135)} = 10.10$, $p < 0.001$, $\eta_p^2 = 0.13$, SCZ, adjusted $p < 0.001$; MDD, adjusted $p = 0.007$) (Table 2 and Figure 1 and 2). Significant differences were found at the Fz (SCZ < HC*, MDD < HC*, $\eta_p^2 = 0.17$), Cz (SCZ < HC*, MDD < HC*, $\eta_p^2 = 0.14$), C3 (SCZ < HC*, $\eta_p^2 = 0.08$), C4 (SCZ < HC*, $\eta_p^2 = 0.10$), and Oz (SCZ < MDD*, $\eta_p^2 = 0.12$) (*adjusted $p < 0.008$) electrodes. Furthermore, patients with MDD showed a larger LDAEP than those with SCZ at the Oz electrode ($p < 0.008$, $\eta_p^2 = 0.12$) after controlling for age, sex, and drug usage (Tables 1 and 2).

In the sub-group analyses, significant correlations were found between age and LDAEP (Table 3 and Figure 3). Age was positively correlated with the Fz ($r = 0.50$, $p < 0.001$), Cz ($r = 0.41$, $p = 0.002$), C3 ($r = 0.51$, $p < 0.001$), and C4 ($r = 0.42$, $p = 0.002$) electrode results and the mean LDAEP ($r = 0.47$, $p < 0.001$) in patients with SCZ. Patients with MDD showed positive correlations between age and the LDAEP at the Fz electrode ($r = 0.45$, $p = 0.001$) and the mean LDAEP ($r = 0.43$, $p = 0.002$).

Significant correlations were found between age and the LDAEP in all patients with SCZ or MDD (Fz, $r = 0.49$, $p < 0.001$; Cz, $r = 0.38$, $p < 0.001$; C3, $r = 0.48$, $p < 0.001$; C4, $r = 0.40$, $p < 0.001$; mean LDAEP, $r = 0.45$, $p < 0.001$). However, symptom severity was not correlated with age or the LDAEP in patients with SCZ or MDD and HCs (Table 3).

Discussion

The current study focused on the disharmonic phenomena between reduction in

Table 2. Demographic data and the results of LDAEP comparison.

VARIABLES	SCZ(a)	MDD(b)	HC(c)	STATISTICS
N	54	51	35	Group-Age, $p = 0.064$
Age (years)	38.98 (16.32)	34.72 (10.98)	41.40 (11.38)	Group-Sex χ^2 , $p = 0.084$
Sex (M/F)	18/36	13/38	17/18	
PANSS				
Positive	29.43 (6.06)			—
Negative	18.69 (6.57)			
General	52.94 (8.50)			
Total	101.06 (14.75)			
HAMD		20.43 (5.42)		
HAMA		22.11 (6.85)		
BDI		28.52 (11.92)	8.54 (7.03)	$t = 9.75$, $p < 0.001$
Accepted LDAEP trials				
60 dB	95.05 (7.44)	97.21 (3.96)	98.80 (1.77)	—
70 dB	95.64 (7.59)	97.72 (3.75)	98.45 (2.24)	
80 dB	95.00 (7.83)	97.68 (3.90)	98.34 (3.13)	
90 dB	94.92 (8.39)	97.82 (3.47)	98.94 (1.89)	
100 dB	94.87 (8.54)	98.02 (2.99)	98.57 (2.62)	
LDAEP slope				<i>Interaction Effect</i>
				Group & LDAEP
				$f = 11.39$, $p < 0.001$, $\eta_p^2 = 0.14$
Mean LDAEP	0.87 (0.68)	0.99 (0.50)	1.48 (0.79)	$a < c^*$, $b < c^*$, $\eta_p^2 = 0.13$
Fz	1.02 (0.94)	0.87 (0.71)	1.95 (1.05)	$a < c^*$, $b < c^*$, $\eta_p^2 = 0.17$
Cz	1.20 (0.88)	1.45 (0.71)	2.08 (1.17)	$a < c^*$, $b < c^*$, $\eta_p^2 = 0.14$
C3	1.05 (0.87)	1.14 (0.62)	1.65 (0.88)	$a < c^*$, $\eta_p^2 = 0.08$
C4	0.93 (0.72)	1.09 (0.51)	1.52 (0.88)	$a < c^*$, $\eta_p^2 = 0.10$
Oz	0.11 (0.32)	0.40 (0.34)	0.18 (0.33)	$a < b^*$, $\eta_p^2 = 0.12$

Bonferroni correction was performed and the significance level was set at $*p < 0.008$.

Mean LDAEP indicates the grand averaged value for Fz, FCz, Cz, Pz, and Oz.

Abbreviations: LDAEP, loudness dependence of auditory evoked potentials; SCZ, schizophrenia; MDD, major depressive disorder; HC, healthy control; PANSS, Positive and Negative Syndrome Scale; BDI, Beck Depression Inventory; M, male; F, female; HAMD, Hamilton Depression Rating Scale; HAMA, Hamilton Anxiety Rating Scale SD, standard deviation.

the LDAEP and the age-related increase in the LDAEP in patients with SCZ and MDD. We observed the following significant results. First, patients with SCZ and MDD showed a lower mean LDAEP than HCs. Second, patients with SCZ showed a lower LDAEP than patients with MDD at the Oz electrode. Third, age was positively correlated with the LDAEP in patients with SCZ and MDD.

A small LDAEP indicates high levels of serotonergic activity in patients with SCZ,²⁸ corroborating the serotonin hypothesis for SCZ.⁴⁹ Serotonin blocking agents are

effective in patients with SCZ because an increased level of serotonergic activity leads to hallucinogenic actions. Additionally, 5-HT_{2A} antagonists improve working memory, learning, and cognitive symptoms by modulating the serotonin system, which affects cognitive functions such as memory, concentration, and learning.⁵⁸ Patients with SCZ had a smaller mean LDAEP at the midline electrodes than HCs. The present study suggests that patients with SCZ have serotonergic dysregulation, which is potentially caused by alterations in serotonergic projections to




Figure 1. Comparison of the slope intensity of the mean loudness dependence of auditory evoked potentials between groups. LDAEP, loudness dependence of auditory evoked potentials; SCZ, schizophrenia; MDD, major depressive disorder; HC, healthy control.

the dorsal hippocampus from the median raphe nucleus of the brainstem, which corresponds with the midline electrodes.⁵⁹ The selected EEG channels are suitable sites for qualifying signals by referencing both mastoids. The long distances from the reference electrodes yielded clear and relatively large amplitudes. Furthermore, EEG signals are generated in pyramidal neurons within the deep cortical areas.^{60,61} The neurons within the cortex are oriented vertically on the scalp, which allows calculation of the EEG sources related to functional changes from the recorded signals on the scalp and functional magnetic resonance imaging.^{62–64} However, the LDAEP was not associated with symptom severity, which was caused by the complex relationships among the LDAEP, serotonin activity,

and clinical symptoms. This argument is associated with the specificities of receptor subtypes for the LDAEP and clinical symptoms. Recently, 5-HT1A was positively correlated with the LDAEP, and serotonin transporter binding was negatively correlated with the LDAEP.²² Regarding the differences among groups at each electrode, patients with SCZ and MDD exhibited a smaller LDAEP than that in HCs. Patients with MDD failed to respond to SSRI administration when they had a low LDAEP, and patients with a high LDAEP were favorable responders.^{34,42} SSRIs facilitate the maintenance of presynaptic serotonergic neurons by inhibiting serotonin transporter binding to its receptor in MDD.⁶⁵ In contrast, patients with MDD showed a higher LDAEP than those with




Figure 2. Comparison of N100 and P200 amplitudes at selected electrodes between groups. SCZ, schizophrenia; MDD, major depressive disorder; HC, healthy control.

SCZ at the Oz electrode. Additionally, patients with MDD showed lower N100 amplitudes in the Cz channel (Supplementary table). Serotonergic deficits are common in patients with MDD even though heterogeneous pathological phenotypes exist.² Changes in serotonergic activity are closely associated with mood changes in MDD, bipolar disorder, and SCZ.⁶⁶⁻⁶⁸ Controversy exists regarding whether the LDAEP reflects the state or is a trait-dependent biomarker of central serotonergic function.^{69,70} The LDAEP could have fluctuated during the investigation according to the status of patients. Thus, longitudinal studies are needed. Moreover, the influence of drug usage should be considered carefully when interpreting the results because it is a

potential factor underlying the influence of drug administration on the serotonin pathway in the human brain.⁷¹

Thus, the findings of this study outlined two critical aspects in relation to the LDAEP. First, patients exhibit a natural decline in serotonergic activity as they get older. Second, both the natural effect of aging and the effects of drugs may act in tandem to decrease serotonin activity. With aging, patients with SCZ might show decreased psychotic symptoms, improved cognitive function, and reduced use of anti-psychotics.⁷² However, the neurophysiological mechanisms of the age-related improvements in SCZ are not clearly understood. Downregulation of serotonin neurotransmission could induce a reduction in

Table 3. Partial correlations among age, LDAEP, and symptom scales in the study groups.

	MDD (n = 51)										
	1	2	3	4	5	6	7	8	9	10	
SCZ (n = 54)											
1. Age	1										
2. Fz	0.50*	1									
3. Cz	0.41*	0.89*	1								
4. C3	0.51*	0.91*	0.93*	1							
5. C4	0.42*	0.83*	0.90*	0.87*	1						
6. Oz	-0.01	0.12	0.25	0.19	0.34	1					
7. Positive	0.25	0.10	0.01	0.10	0.08	-0.02	1				
8. Negative	0.09	0.30	0.34	0.32	0.26	0.13	-0.02	1			
9. General	-0.02	0.27	0.29	0.29	0.36	0.14	0.30	0.28	1		
10. Total	0.13	0.33	0.32	0.35	0.36	0.13	0.59*	0.60*	0.83*	1	
11. Mean LDAEP	0.47*	0.94*	0.97*	0.96*	0.94*	0.32	0.07	0.32	0.32	0.36	1
SCZ + MDD (n = 105)											
1. Age	1										
2. Fz	0.49*	1									
3. Cz	0.38*	0.86*	1								
4. C3	0.48*	0.88*	0.91*	1							
5. C4	0.40*	0.80*	0.89*	0.84*	1						
6. Oz	0.06	0.13	0.34	0.24	0.41*	1					
7. Mean LDAEP	0.45*	0.92*	0.96*	0.95*	0.93*	0.39*	1				
MDD (n = 51)											
1. Age	1										
2. Fz	0.45*	1									
3. Cz	0.35	0.82*	1								
4. C3	0.41	0.84*	0.88*	1							
5. C4	0.37	0.76*	0.86*	0.79*	1						
6. Oz	0.19	0.14	0.40	0.32	0.47*	1					
7. HAMD	0.07	0.04	-0.01	-0.04	0.01	0.14	1				
8. HAMA	0.12	0.11	0.09	0.06	0.07	0.18	0.83*	1			
9. BDI	-0.12	0.06	0.09	0.07	0.13	0.29	0.57*	0.58*	1		
10. Mean LDAEP	0.43*	0.89*	0.96*	0.93*	0.91*	0.46*	0.01	0.10	0.18	1	
HC (n = 35)											
1. Age	1										
2. Fz	-0.03	1									
3. Cz	-0.17	0.92*	1								
4. C3	-0.17	0.92*	0.94*	1							
5. C4	-0.22	0.83*	0.86*	0.83*	1						
6. Oz	-0.22	0.32	0.34	0.41	0.37	1					
7. BDI	0.03	-0.23	-0.21	-0.23	-0.16	0.04	1				
8. Mean LDAEP	-0.16	0.95*	0.97*	0.97*	0.91*	0.45	-0.21	1			

Bold values indicate significant age-LDAEP correlations.

*Significance level was set at the Bonferroni corrected p-value ($p < 0.003$). Medication and sex were controlled.

Abbreviations: LDAEP, loudness dependence of auditory evoked potentials; SCZ, schizophrenia; MDD, major depressive disorder; BDI, Beck Depression Inventory; HAMD, Hamilton Depression Rating Scale; HAMA, Hamilton Anxiety Rating Scale.




Figure 3. Partial correlations between age and mean loudness dependence of auditory evoked potentials. *Significance level was set at an adjusted p-value ($p < 0.003$). LDAEP, loudness dependence of auditory evoked potentials; SCZ, schizophrenia; MDD, major depressive disorder; HC, healthy control.

clinical symptoms and relief of cognitive impairment in older SCZ patients.^{73,74} This is partially consistent with the results from the current cross-sectional study, which observed correlations between age and the LDAEP. However, there was no effect of age in HCs. A correlation between age and duration of illness could be observed for people with psychiatric disorders, which would worsen the physical health outcome,⁷⁵ but healthy individuals might appear to be less affected by aging. In addition, comparisons of the LDAEP among drug naive patients or those using the same types of drugs should be examined to control for specific pharmacological effects. Further studies are warranted to elucidate the relationship between aging and clinical domains such as cognitive function, motor behaviors, and sub-clinical symptoms after controlling for medications. Age-related changes in brain disorders have not been fully explored. The natural decline in serotonin during aging could affect cognitive and sensory functions. In pathological conditions, both functional and negative effects may exist because of serotonin reduction. Our finding is a stepping stone toward understanding the neurophysiological mechanisms of age and serotonergic function.

This study had some limitations. Drug usage and dosage data were not fully controlled, and information regarding

parameters such as the duration of illness was lacking. Moreover, the sample size was insufficient to verify the present results. Future longitudinal studies with larger sample sizes and full pharmacological history details could help expand our findings.

The current study was conducted to explain the paradoxical relationship between the lower LDAEP in patients with MDD and SCZ compared with that in HCs and the age-related increase in the LDAEP in patients with SCZ and MDD. In conclusion, the reduction of central serotonergic activity with age in patients with SCZ and MDD may be screened using the LDAEP. Thus, LDAEP assessments may be used to predict treatment responses in relation to the effect of age in patients with MDD and SCZ.

Acknowledgements

This study was pre-printed without peer review and is linked at the three websites listed below.

1. https://www.researchgate.net/publication/353961196_Association_Between_The_Loudness_Dependence_of_The_Auditory_Evoked_Potential_and_Age_in_Patients_With_Schizophrenia_and_Depression
2. https://assets.researchsquare.com/files/rs-711908/v1/4fe01004-e905-4672-afb7-166https://www.researchgate.net/publication/353961196_Association_Between_The_Loudness_Dependence_of_The_Auditory_Evoked_Potential_and_Age_in_Patients_With_Schizoph

renia_and_Depression61008481.pdf?c=1634549362

3. <https://europepmc.org/article/ppr/ppr383677>

Author contributions

K-IJ and J-HC contributed to the conception and design of the study. K-IJ and CL contributed to the acquisition and analysis of data. K-IJ contributed to drafting the article. K-IJ, SK, CL, and J-HC contributed to the review of the article. J-HC and CL contributed to the supervision of the study. All authors approved the final version of the article.

Declaration of conflicting interest

All authors declare no conflicts of interest.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by a grant from the Korea Health Technology R&D project through the Korea Health Industry Development Institute (KHIDI) (HI17C2272) and by the KBRI Basic Research Program through the Korea Brain Research Institute, which is funded by the Ministry of Science and ICT (22-BR-03-01). This study was also supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (NRF-2021R1A6A3A01086699).

ORCID iD

Kuk-In Jang  <https://orcid.org/0000-0002-7405-3899>

Supplemental material

Supplemental material for this article is available online.

References

1. Clayton AH, Baker RA, Sheehan JJ, et al. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients

- beginning adjunctive treatment in a 52-week, open-label study. *BMC Res Notes* 2014; 7: 459. 2014/07/20. doi: 10.1186/1756-0500-7-459.
2. Underwood MD, Kassir SA, Bakalian MJ, et al. Serotonin receptors and suicide, major depression, alcohol use disorder and reported early life adversity. *Transl Psychiatry* 2018; 8: 279. doi: 10.1038/s41398-018-0309-1.
3. O'Connor FL. The role of serotonin and dopamine in schizophrenia. *Journal of the American Psychiatric Nurses Association* 1998; 4: S30–S34. doi: [https://doi.org/10.1016/S1078-3903\(98\)90006-4](https://doi.org/10.1016/S1078-3903(98)90006-4).
4. Cowen PJ and Browning M. What has serotonin to do with depression? *World Psychiatry* 2015; 14: 158–160. 2015/06/05. doi: 10.1002/wps.20229.
5. Eggers AE. A serotonin hypothesis of schizophrenia. *Med Hypotheses* 2013; 80: 791–794. 2013/04/06. doi: 10.1016/j.mehy.2013.03.013.
6. Bhatt S, Devadoss T, Manjula SN, et al. 5-HT₃ receptor antagonism: a potential therapeutic approach for the treatment of depression and other disorders. *Curr Neuropharmacol* 2021; 19: 1545–1559. 2020/10/17. doi: 10.2174/1570159x18666201015155816.
7. Ozcan H, Aydın N, Aydın MD, et al. Olfactory bulbectomy and raphe nucleus relationship: a new vision for well-known depression model. *Nord J Psychiatry* 2020; 74: 194–200. 2019/11/15. doi: 10.1080/08039488.2019.1689294.
8. Tsegay EW, Demise DG, Hailu NA, et al. Serotonin type 6 and 7 receptors as a novel therapeutic target for the treatment of schizophrenia. *Neuropsychiatr Dis Treat* 2020; 16: 2499–2509. 2020/11/06. doi: 10.2147/ndt.S263424.
9. Maffioletti E, Valsecchi P, Minelli A, et al. Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients. *Drug Dev Res* 2020; 81: 754–761. 2020/05/29. doi: 10.1002/ddr.21686.
10. Rush AJ, Kraemer HC, Sackeim HA, et al. Report by the ACNP Task Force on response and remission in major depressive

- disorder. *Neuropsychopharmacology* 2006; 31: 1841–1853. 2006/06/24. doi: 10.1038/sj.npp.1301131.
11. Park YM. The hypothesis on the prediction of treatment response with buspirone augmentation along with serotonergic antidepressant in patients with major depressive disorder using loudness dependence of auditory evoked potentials: Two cases and review of the literature for evidence. *Psychiatry Investig* 2020; 17: 222–224. 2020/03/11. doi: 10.30773/pi.2019.0293.
 12. Gener T, Tauste Campo A, Alemany-González M, et al. Serotonin 5-HT(1A), 5-HT(2A) and dopamine D(2) receptors strongly influence prefronto-hippocampal neural networks in alert mice: Contribution to the actions of risperidone. *Neuropharmacology* 2019; 158: 107743. 2019/08/21. doi: 10.1016/j.neuropharm.2019.107743.
 13. Uhl I, Kulik A, Roser P, et al. Central serotonergic function in patients with predominantly negative symptoms of schizophrenia. *Schizophr Res* 2018; 193: 443–444. 2017/06/24. doi: 10.1016/j.schres.2017.05.041.
 14. Lee S, Jang KI and Chae JH. Association of the loudness dependence of auditory evoked potentials with clinical changes to repetitive transcranial magnetic stimulation in patients with depression. *J Affect Disord* 2018; 238: 451–457. 2018/06/20. doi: 10.1016/j.jad.2018.05.023.
 15. Jang KI, Lee SH, Huh HJ, et al. Influence of the 5-HT3A receptor gene polymorphism and childhood sexual trauma on central serotonin activity. *PloS one* 2015; 10: e0145269. 2015/12/25. doi: 10.1371/journal.pone.0145269.
 16. Lee BH, Park YM, Lee SH, et al. Serum levels of tumor necrosis factor- α and loudness dependence of auditory evoked potentials at pretreatment and posttreatment in patients with major depressive disorder. *Brain sciences* 2019; 9: 253. 2019/09/29. doi: 10.3390/brainsci9100253.
 17. Park YM and Lee SH. Clinical usefulness of loudness dependence of auditory evoked potentials (LDAEP) in patients with bipolar disorder. *Psychiatry Investig* 2013; 10: 233–237. 2013/12/05. doi: 10.4306/pi.2013.10.3.233.
 18. Park YM, Lee SH, Kim S, et al. The loudness dependence of the auditory evoked potential (LDAEP) in schizophrenia, bipolar disorder, major depressive disorder, anxiety disorder, and healthy controls. *Prog Neuropsychopharmacol Biol Psychiatry* 2010; 34: 313–316. 2009/12/17. doi: 10.1016/j.pnpbp.2009.12.004.
 19. Park YM, Jung E, Kim HS, et al. Differences in central serotonergic transmission among patients with recent onset, sub-chronic, and chronic schizophrenia as assessed by the loudness dependence of auditory evoked potentials. *Schizophr Res* 2015; 168: 180–184. 2015/08/04. doi: 10.1016/j.schres.2015.07.036.
 20. Kim JS, Kim DW, Kwon YJ, et al. The relationship between auditory evoked potentials and symptoms of attention-deficit/hyperactivity disorder in adult patients with major depressive disorder. *Int J Psychophysiol* 2019; 142: 50–56. 2019/06/18. doi: 10.1016/j.ijpsycho.2019.06.008.
 21. Park YM, Kim DW, Kim S, et al. The loudness dependence of the auditory evoked potential (LDAEP) as a predictor of the response to escitalopram in patients with generalized anxiety disorder. *Psychopharmacology (Berl)* 2011; 213: 625–632. 2010/11/09. doi: 10.1007/s00213-010-2061-y.
 22. Pillai RLI, Bartlett EA, Ananth MR, et al. Examining the underpinnings of loudness dependence of auditory evoked potentials with positron emission tomography. *NeuroImage* 2020; 213: 116733. 2020/03/15. doi: 10.1016/j.neuroimage.2020.116733.
 23. Hegerl U, Bottlender R, Gallinat J, et al. The serotonin syndrome scale: First results on validity. *Eur Arch Psychiatry Clin Neurosci* 1998; 248: 96–103. 1998/07/31. doi: 10.1007/s004060050024.
 24. Hegerl U and Juckel G. Identifying psychiatric patients with serotonergic dysfunctions by event-related potentials. *World J Biol Psychiatry* 2000; 1: 112–118. 2003/02/28. doi: 10.3109/15622970009150574.
 25. O'Neill BV, Croft RJ and Nathan PJ. The loudness dependence of the auditory evoked potential (LDAEP) as an in vivo biomarker of central serotonergic function in humans:

- Rationale, evaluation and review of findings. *Hum Psychopharmacol* 2008; 23: 355–370. 2008/04/19. doi: 10.1002/hup.940.
26. Juckel G, Hegerl U, Molnár M, et al. Auditory evoked potentials reflect serotonergic neuronal activity—a study in behaving cats administered drugs acting on 5-HT_{1A} autoreceptors in the dorsal raphe nucleus. *Neuropsychopharmacology* 1999; 21: 710–716. 2000/01/14. doi: 10.1016/s0893-133x(99)00074-3.
 27. Gudlowski Y, Ozgürdal S, Witthaus H, et al. Serotonergic dysfunction in the prodromal, first-episode and chronic course of schizophrenia as assessed by the loudness dependence of auditory evoked activity. *Schizophr Res* 2009; 109: 141–147. 2009/03/10. doi: 10.1016/j.schres.2009.02.008.
 28. Juckel G, Gudlowski Y, Müller D, et al. Loudness dependence of the auditory evoked N1/P2 component as an indicator of serotonergic dysfunction in patients with schizophrenia—a replication study. *Psychiatry Res* 2008; 158: 79–82. 2007/12/22. doi: 10.1016/j.psychres.2007.08.013.
 29. Kim JS, Kim S, Lee HS, et al. Auditory evoked potentials and suicidal behaviors in patients with major depressive disorders. *Sci Rep* 2021; 11: 7255. 2021/04/02. doi: 10.1038/s41598-021-86602-7.
 30. Park YM. Relationship between auditory evoked potentials and circadian preference in patients with major depressive episodes. *Brain Sci* 2020; 10: 370. 2020/06/18. doi: 10.3390/brainsci10060370.
 31. Juckel G, Gallinat J, Riedel M, et al. Serotonergic dysfunction in schizophrenia assessed by the loudness dependence measure of primary auditory cortex evoked activity. *Schizophr Res* 2003; 64: 115–124. 2003/11/14. doi: 10.1016/s0920-9964(03)00016-1.
 32. Hagenmuller F, Heekeren K, Meier M, et al. The loudness dependence of auditory evoked potentials (LDAEP) in individuals at risk for developing bipolar disorders and schizophrenia. *Clin Neurophysiol* 2016; 127: 1342–1350. 2015/12/08. doi: 10.1016/j.clinph.2015.10.050.
 33. Toscano M, Viganò A, Jannini TB, et al. Intensity-dependence of auditory evoked potentials (IDAP) as a neurophysiological parameter to predict anti-aggressive responsiveness to SSRI treatment. *Front Pharmacol* 2021; 12: 716338. 2021/08/31. doi: 10.3389/fphar.2021.716338.
 34. Lee BH, Park YM, Lee SH, et al. Prediction of long-term treatment response to selective serotonin reuptake inhibitors (SSRIs) using scalp and source loudness dependence of auditory evoked potentials (LDAEP) analysis in patients with major depressive disorder. *Int J Mol Sci* 2015; 16: 6251–6265. 2015/03/21. doi: 10.3390/ijms16036251.
 35. Roberts C, Sahakian BJ and Robbins TW. Psychological mechanisms and functions of 5-HT and SSRIs in potential therapeutic change: Lessons from the serotonergic modulation of action selection, learning, affect, and social cognition. *Neurosci Biobehav Rev* 2020; 119: 138–167. 2020/09/16. doi: 10.1016/j.neubiorev.2020.09.001.
 36. Juza R, Vlcek P, Mezeiova E, et al. Recent advances with 5-HT₃ modulators for neuropsychiatric and gastrointestinal disorders. *Med Res Rev* 2020; 40: 1593–1678. 2020/03/03. doi: 10.1002/med.21666.
 37. Fakhoury M. Revisiting the serotonin hypothesis: Implications for major depressive disorders. *Mol Neurobiol* 2016; 53: 2778–2786. 2015/04/01. doi: 10.1007/s12035-015-9152-z.
 38. Bleich A, Brown SL, Kahn R, et al. The role of serotonin in schizophrenia. *Schizophr Bull* 1988; 14: 297–315. 1988/01/01. doi: 10.1093/schbul/14.2.297.
 39. Schmidt CJ, Kehne JH, Carr AA, et al. Contribution of serotonin neurotoxins to understanding psychiatric disorders: The role of 5-HT₂ receptors in schizophrenia and antipsychotic activity. *Int Clin Psychopharmacol* 1993; 8 Suppl 2: 25–32. 1993/11/01.
 40. Morrissette DA and Stahl SM. Modulating the serotonin system in the treatment of major depressive disorder. *CNS Spectr* 2014; 19: 54–68. 2014/12/29. doi: 10.1017/S1092852914000613.
 41. Linka T, Sartory G, Bender S, et al. The intensity dependence of auditory ERP components in unmedicated patients with major depression and healthy controls. An analysis

- of group differences. *J Affect Disord* 2007; 103: 139–145. 2007/02/24. doi: 10.1016/j.jad.2007.01.018.
42. Park YM, Lee SH and Park EJ. Usefulness of LDAEP to predict tolerability to SSRIs in major depressive disorder: A case report. *Psychiatry Investig* 2012; 9: 80–82. 2012/01/17. doi: 10.4306/pi.2012.9.1.80.
 43. Lee TW, Yu YWY, Chen TJ, et al. Loudness dependence of the auditory evoked potential and response to antidepressants in Chinese patients with major depression. *J Psychiatry Neurosci* 2005; 30: 202–205.
 44. Min J-A, Lee S-H, Lee S-Y, et al. Clinical characteristics associated with different strengths of loudness dependence of auditory evoked potentials (LDAEP) in major depressive disorder. *Psychiatry Res* 2012; 200: 374–381. doi: <https://doi.org/10.1016/j.psychres.2012.06.038>.
 45. Meltzer CC, Smith G, DeKosky ST, et al. Serotonin in aging, late-life depression, and Alzheimer's disease: The emerging role of functional imaging. *Neuropsychopharmacology* 1998; 18: 407–430. doi: 10.1016/S0893-133X(97)00194-2.
 46. Chakraborty TS, Gendron CM, Lyu Y, et al. Sensory perception of dead conspecifics induces aversive cues and modulates lifespan through serotonin in *Drosophila*. *Nat Commun* 2019; 10: 2365–2365. doi: 10.1038/s41467-019-10285-y.
 47. Linford NJ, Kuo TH, Chan TP, et al. Sensory perception and aging in model systems: From the outside in. *Annu Rev Cell Dev Biol* 2011; 27: 759–785. 2011/07/13. doi: 10.1146/annurev-cellbio-092910-154240.
 48. McEntee WJ and Crook TH. Serotonin, memory, and the aging brain. *Psychopharmacology (Berl)* 1991; 103: 143–149. 1991/01/01. doi: 10.1007/bf02244194.
 49. Lewis R, Kapur S, Jones C, et al. Serotonin 5-HT₂ receptors in schizophrenia: A PET study using [¹⁸F]setoperone in neuroleptic-naïve patients and normal subjects. *The Am J Psychiatry* 1999; 156: 72–78. 1999/01/19. doi: 10.1176/ajp.156.1.72.
 50. Kay SR, Fiszbein A and Opler LA. The Positive and Negative Syndrome scale (PANSS) for Schizophrenia. *Schizophr Bull* 1987; 13: 261–276. doi: 10.1093/schbul/13.2.261%J Schizophrenia Bulletin.
 51. Hamilton M. The assessment of anxiety states by rating. *Br J Med Psychol* 1959; 32: 50–55. 1959/01/01. doi: 10.1111/j.2044-8341.1959.tb00467.x.
 52. Hamilton M. A rating scale for depression. *J Neurol Neurosurg Psychiatry* 1960; 23: 56–62. doi: 10.1136/jnnp.23.1.56.
 53. Song Y-M, Lee H-K, Kim JW, et al. Reliability and Validity of the Korean Version of Beck Depression Inventory-II via the Internet: Results from a University Student sample. *J Korean Neuropsychiatr Assoc* 2012; 51: 402–408.
 54. Von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. *Ann Intern Med* 2007; 147: 573–577. 2007/10/17. doi: 10.7326/0003-4819-147-8-200710160-00010.
 55. Semlitsch HV, Anderer P, Schuster P, et al. A solution for reliable and valid reduction of ocular artifacts, applied to the P300 ERP. *Psychophysiology* 1986; 23: 695–703. 1986/11/01.
 56. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. *Biometrika* 1988; 75: 800–802. doi: 10.2307/2336325.
 57. Faul F, Erdfelder E, Lang AG, et al. G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behav Res Methods* 2007; 39: 175–191. 2007/08/19. doi: 10.3758/bf03193146.
 58. Švob Štrac D, Pivac N and Mück-Šeler D. The serotonergic system and cognitive function. *Transl Neurosci* 2016; 7: 35–49. doi: 10.1515/tnsci-2016-0007.
 59. Kusljic S and Van Den Buuse M. Differential role of serotonin projections from the dorsal and median raphe nuclei in phencyclidine-induced hyperlocomotion and fos-like immunoreactivity in rats. *Synapse (New York, NY)* 2012; 66: 885–892. 2012/06/27. doi: 10.1002/syn.21580.
 60. Traub RD, Hawkins K, Adams NE, et al. Layer 4 pyramidal neuron dendritic bursting underlies a post-stimulus visual cortical

- alpha rhythm. *Commun Biol* 2020; 3: 230. 2020/05/13. doi: 10.1038/s42003-020-0947-8.
61. Kirschstein T and Köhling R. What is the Source of the EEG? *Clinical EEG and Neuroscience* 2009; 40: 146–149. doi: 10.1177/155005940904000305.
 62. Avitan L, Teicher M and Abeles M. EEG generator — a model of potentials in a volume conductor. *J Neurophysiol* 2009; 102: 3046–3059. doi: 10.1152/jn.91143.2008.
 63. Grech R, Cassar T, Muscat J, et al. Review on solving the inverse problem in EEG source analysis. *J Neuroeng Rehabil* 2008; 5: 25. doi: 10.1186/1743-0003-5-25.
 64. Biscay RJ, Bosch-Bayard JF and Pascual-Marqui RD. Unmixing EEG inverse solutions based on brain segmentation. *Front Neurosci* 2018; 12: 325. Methods. doi: 10.3389/fnins.2018.00325.
 65. Liu B, Liu J, Wang M, et al. From serotonin to neuroplasticity: Evolvement of theories for major depressive disorder. *Front Cell Neurosci* 2017; 11: 305. 2017/10/17. doi: 10.3389/fncel.2017.00305.
 66. Shiah IS and Yatham LN. Serotonin in mania and in the mechanism of action of mood stabilizers: A review of clinical studies. *Bipolar Disord* 2000; 2: 77–92. 2001/03/17. doi: 10.1034/j.1399-5618.2000.020201.x.
 67. Lee KS, Park YM and Lee SH. Serotonergic dysfunction in patients with bipolar disorder assessed by the loudness dependence of the auditory evoked potential. *Psychiatry Investig* 2012; 9: 298–306. 2012/09/06. doi: 10.4306/pi.2012.9.3.298.
 68. Marek GJ and Aghajanian GK. The electrophysiology of prefrontal serotonin systems: Therapeutic implications for mood and psychosis. *Biol Psychiatry* 1998; 44: 1118–1127. doi: [https://doi.org/10.1016/S0006-3223\(98\)00036-5](https://doi.org/10.1016/S0006-3223(98)00036-5).
 69. Kim JS, Kim S, Jung W, et al. Auditory evoked potential could reflect emotional sensitivity and impulsivity. *Sci Rep* 2016; 6: 37683. doi: 10.1038/srep37683.
 70. Hwang M, Lee YJ, Lee M, et al. Relationship between the loudness dependence of the auditory evoked potential and the severity of suicidal ideation in patients with major depressive disorder. *Clin Psychopharmacol Neurosci* 2021; 19: 323–333. 2021/04/24. doi: 10.9758/cpn.2021.19.2.323.
 71. Meltzer HY. The role of serotonin in antipsychotic drug action. *Neuropsychopharmacology* 1999; 21: 106–115. doi: 10.1016/S0893-133X(99)00046-9.
 72. Jeste DV and Maglione JE. Treating older adults with schizophrenia: Challenges and opportunities. *Schizophr Bull* 2013; 39: 966–968. 2013/04/03. doi: 10.1093/schbul/sbt043.
 73. Shimizu S, Mizuguchi Y and Ohno Y. Improving the treatment of schizophrenia: Role of 5-HT receptors in modulating cognitive and extrapyramidal motor functions. *CNS Neurol Disord Drug Targets* 2013; 12: 861–869. 2013/07/13. doi: 10.2174/18715273113129990088.
 74. Nasrallah H, Fedora R and Morton R. S114. Efficacy of the serotonin 5HT-2a inverse agonist pimavanserin in refractory hallucinations and delusions that failed to respond to clozapine or other antipsychotics. *Schizophrenia bulletin* 2019; 45: S350–S350. 2019/04/09. doi: 10.1093/schbul/sbz020.659.
 75. Han LKM, Verhoeven JE, Tyrka AR, et al. Accelerating research on biological aging and mental health: Current challenges and future directions. *Psychoneuroendocrinology* 2019; 106: 293–311. 2019/04/05. doi: 10.1016/j.psyneuen.2019.04.004.